TY - JOUR
T1 - Pediatric Moyamoya Biomarkers
T2 - Narrowing the Knowledge Gap
AU - Lehman, Laura L.
AU - Kaseka, Matsanga Leyila
AU - Stout, Jeffery
AU - See, Alfred P.
AU - Pabst, Lisa
AU - Sun, Lisa R.
AU - Hassanein, Sahar A.
AU - Waak, Michaela
AU - Vossough, Arastoo
AU - Smith, Edward R.
AU - Dlamini, Nomazulu
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10
Y1 - 2022/10
N2 - Moyamoya is a progressive cerebrovascular disorder that leads to stenosis of the arteries in the distal internal carotid, proximal middle cerebral and proximal anterior cerebral arteries of the circle of Willis. Typically a network of collaterals form to bypass the stenosis and maintain cerebral blood flow. As moyamoya progresses it affects the anterior circulation more commonly than posterior circulation, and cerebral blood flow becomes increasingly reliant on external carotid supply. Children with moyamoya are at increased risk for ischemic symptoms including stroke and transient ischemic attacks (TIA). In addition, cognitive decline may occur over time, even in the absence of clinical stroke. Standard of care for stroke prevention in children with symptomatic moyamoya is revascularization surgery. Treatment of children with asymptomatic moyamoya with revascularization surgery however remains more controversial. Therefore, biomarkers are needed to assist with not only diagnosis but also with determining ischemic risk and identifying best surgical candidates. In this review we will discuss the current knowledge as well as gaps in research in relation to pediatric moyamoya biomarkers including neurologic presentation, cognitive, neuroimaging, genetic and biologic biomarkers of disease severity and ischemic risk.
AB - Moyamoya is a progressive cerebrovascular disorder that leads to stenosis of the arteries in the distal internal carotid, proximal middle cerebral and proximal anterior cerebral arteries of the circle of Willis. Typically a network of collaterals form to bypass the stenosis and maintain cerebral blood flow. As moyamoya progresses it affects the anterior circulation more commonly than posterior circulation, and cerebral blood flow becomes increasingly reliant on external carotid supply. Children with moyamoya are at increased risk for ischemic symptoms including stroke and transient ischemic attacks (TIA). In addition, cognitive decline may occur over time, even in the absence of clinical stroke. Standard of care for stroke prevention in children with symptomatic moyamoya is revascularization surgery. Treatment of children with asymptomatic moyamoya with revascularization surgery however remains more controversial. Therefore, biomarkers are needed to assist with not only diagnosis but also with determining ischemic risk and identifying best surgical candidates. In this review we will discuss the current knowledge as well as gaps in research in relation to pediatric moyamoya biomarkers including neurologic presentation, cognitive, neuroimaging, genetic and biologic biomarkers of disease severity and ischemic risk.
UR - http://www.scopus.com/inward/record.url?scp=85140875387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140875387&partnerID=8YFLogxK
U2 - 10.1016/j.spen.2022.101002
DO - 10.1016/j.spen.2022.101002
M3 - Article
C2 - 36344019
AN - SCOPUS:85140875387
SN - 1071-9091
VL - 43
JO - Seminars in Pediatric Neurology
JF - Seminars in Pediatric Neurology
M1 - 101002
ER -